Study on Efficacy and Safety of CBLB612 for Neutropenia Prophylaxis
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Double blind, randomized, placebo-controlled, multicenter pilot study on efficacy and safety
of CBLB612 following single administration for neutropenia prophylaxis in breast cancer
patients receiving doxorubicin and cyclophosphamide myelosuppressive chemotherapy